Laboratorios Farmaceuticos Rovi, S.A.
LABFF
Other OTC90.61
USD
- -
- -
ISIN
ES0157261019
Return %
Stock
S&P500
1Y
- -
26.53
3Y
77.32
76.60
5Y
33.68
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Juan Lopez-Belmonte Encina
- Full Time Employees
- 2,197
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Calle José Isbert, 2 Madrid Spain 28223
- IPO Date
- Apr 5, 2021
- Website
- rovi.es
- Similar Companies
- Business
- Laboratorios Farmaceuticos Rovi, S.A. operates as a comprehensive pharmaceutical enterprise, dedicated to the investigation, progression, fabrication, and commercialization of a diverse array of pharmaceutical products across Spain, the European Union, OECD nations, and other international markets. The company also handles the distribution of various therapeutics licensed from other laboratories. Its principal offerings include key low-molecular-weight heparins such as Hibor, utilized for the prophylaxis and management of venous thromboembolic conditions, and Enoxaparin biosimilar, known as Becat, which serves a similar anticoagulant purpose. The portfolio extends to cardiovascular treatments like Neparvis for symptomatic chronic heart failure with reduced ejection fraction in adults, and Orvatez for the dietary management of hypercholesterolemia. In the respiratory domain, Rovi provides long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler for the maintenance care of chronic obstructive pulmonary diseases. Furthermore, the company markets Volutsa for addressing moderate to severe storage and voiding symptoms associated with benign prostatic hyperplasia in men unresponsive to monotherapy, alongside Medikinet and Medicebrán for the treatment of attention deficit hyperactivity disorder in pediatric and adolescent patients. A significant recent expansion includes Okedi (Risperidone ISM) for schizophrenia, which has seen international launches in various markets including Finland, Canada, and other Nordic countries, with further expansion planned for Australia, Taiwan, and the Netherlands. Beyond prescription medicines, Rovi also offers an extensive range of hospital products for imaging diagnostics, encompassing agents like Iomeron and Iopamiro for computed tomography and interventional procedures, Multihance and Prohance for magnetic resonance imaging, and Sonovue for ultrasounds. These are complemented by advanced contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with their compatible disposable materials. The company has recently ventured into artificial intelligence by acquiring a majority stake in Cells IA Technologies, S.L., aiming to enhance diagnosis in pathological anatomy. Rovi maintains a significant presence in contract manufacturing, providing comprehensive services to other pharmaceutical entities for a wide spectrum of dosage forms, including pre-filled syringes, vials, suppositories, tablets, hard capsules, and sachets. Its manufacturing facilities, located in Spain, are approved by the FDA and adhere to EMA/EU GMP Annex-1 standards, enabling the production of high-value-added injectables. The company engages with wholesalers, medical practitioners, nursing professionals, pharmacists, and patients. A notable long-term collaboration involves Moderna, Inc., where Rovi supports the manufacturing, including compounding, aseptic filling, inspection, labeling, and packaging of Moderna's mRNA COVID-19 vaccine, Spikevax, and future mRNA vaccine candidates for numerous international markets. This partnership has seen FDA approval for some of Rovi's Spanish plants to produce the vaccine for the U.S. market. Founded in 1946, Laboratorios Farmaceuticos Rovi, S.A. is headquartered in Pozuelo de Alarcón, Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L. The company is currently exploring strategic alternatives for its contract manufacturing division, having received non-binding acquisition offers.
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q1 2026 Earnings Call Transcript
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q4 2025 Earnings Call Transcript
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Shareholder/Analyst Call Transcript
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q2 2025 Earnings Call Transcript
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) 2024 Financial Results Earnings Call Transcript